Theratechnologies has accumulated valuable knowledge and expertise in the field of therapeutic peptides.  In addition to being efficacious at very low doses, these molecules are highly specific, thus reducing the risk of toxicity and side-effects.

However, despite their significant therapeutic potential, peptides are unstable in serum and hence often incompatible for clinical use. Our stabilization technology, called LAP (Long Acting Peptides), increases the resistance of peptides to enzymatic degradation. The result is a much more stable product that offers greater clinical efficacy and presents an excellent specificity and safety profile.

Theratechnologies owns another original platform technology called ExoPep, which is aimed at the rapid discovery of peptides that interact with G protein-coupled receptors (GPCR). An important number of currently available prescription drugs interact with these receptors.